论文部分内容阅读
目的:探讨P糖蛋白(P-gp)、多药耐药相关蛋白(MRP)、肺耐药蛋白(LRP)、P53蛋白及c-erbB-2蛋白在术前未经治疗的非小细胞肺癌(NSCLC)中的表达及相互间的关系。方法:采用免疫组化法检测78例NSCLC癌组织及15例癌旁肺组织(距癌灶5 cm)中P-gp、MRP、LRP、P53及c-erbB-2的蛋白表达情况。结果:免疫组化显示P-gp、MRP、LRP、P53及c-erbB-2在肺癌组织中的阳性表达率分别是65.4%(51/78)、39.7%(31/78)、56.4%(44/78)、53.8%(42/78)及43.6%(34/78),均显著高于癌旁肺组织中的表达水平(P<0.05);MRP和LRP蛋白表达在不同病理类型(腺癌、鳞癌及大细胞癌)之间比较均具有显著性差异(P分别为0.008和<0.001),LRP及P53蛋白表达在不同病理分化程度之间具有显著性差异(P分别为0.025和0.026);c-erbB-2表达与P-gp、MRP、LRP、P53均有相关性(Spearman相关系数分别为0.317、0.401、0.519和0.341,P值分别为0.005、<0.001、<0.001和0.002),P53与MRP之间(Spearman相关系数为=0.260,P=0.022)以及LRP与MRP之间(Spearman相关系数为0.371,P=0.001)有相关性。结论:P-gp、MRP、LRP、P53及c-erbB-2这些蛋白的表达在NSCLC的多药耐药形成及肿瘤的发生发展中可能具有一定的协同作用。
Objective: To investigate the expression of P-gp, MRP, LRP, P53 and c-erbB-2 protein in preoperative untreated non-small cell lung cancer (NSCLC) in the expression and mutual relations. Methods: The protein expressions of P-gp, MRP, LRP, P53 and c-erbB-2 in 78 cases of NSCLC and 15 cases of paracancer lung tissues (5 cm away from the tumor) were detected by immunohistochemistry. Results: The positive rates of P-gp, MRP, LRP, P53 and c-erbB-2 in lung cancer tissues were 65.4% (51/78), 39.7% (31/78) and 56.4% 44/78), 53.8% (42/78) and 43.6% (34/78), respectively, which were significantly higher than those in adjacent lung tissues (P <0.05). The expression of MRP and LRP in different pathological types Cancer, squamous cell carcinoma and large cell carcinoma) (P = 0.008 and <0.001 respectively). There was significant difference in the expression of LRP and P53 between different pathological grades (P = 0.025 and 0.026 ). The correlation between c-erbB-2 and P-gp, MRP, LRP and P53 was significant (Spearman correlation coefficient was 0.317,0.401,0.519 and 0.341, P values were 0.005, <0.001, <0.001 and 0.002 respectively) , P53 and MRP (Spearman correlation coefficient = 0.260, P = 0.022), and correlation between LRP and MRP (Spearman correlation coefficient 0.371, P = 0.001). CONCLUSION: The expressions of P-gp, MRP, LRP, P53 and c-erbB-2 may play synergistic roles in the multidrug resistance of NSCLC and tumorigenesis.